These results where shared as a late-breaking abstract at the EAN 2019 and simultaneously published [2]. First author Dr Johannes Levin (Ludwig-Maximilians-University of Munich, Germany) explained that the polyphenol EGCG inhibits α-synuclein aggregation in higher doses. A dozen specialist centres in Germany participated in the trial. In total, 92 participants were randomly assigned to oral EGCG 400 mg or matching placebo once daily for 4 weeks, then twice daily for 4 weeks, followed by three times daily for 40 weeks; 63 patients completed the study per protocol.
After 52 weeks, there was no difference in change from baseline in motor examination scores on the Unified Multiple System Atrophy Rating Scale (UMSARS), which was the primary endpoint. The UMSARS score was 5.66 and 6.60 in the EGCG and placebo group, respectively (P=0.51). An MRI analysis in 19 patients treated per protocol revealed a significant reduction of over 50% in brain atrophy rate. Two patients in the EGCG group had to stop treatment because of severe hepatotoxicity. This is why, according to Dr Levin, doses of more than 1,200 mg should be avoided.
1. Höglinger G, et al. EAN 2019, PLEN 04_6.
2. Levin J, et al. Lancet Neurol. 2019;18(8):724-35.
Posted on
Previous Article
« Motor nerve biopsy for early diagnosis of lower motor neuron syndromes Next Article
Haematoma expansion and mortality in intracerebral haemorrhage after OAC »
« Motor nerve biopsy for early diagnosis of lower motor neuron syndromes Next Article
Haematoma expansion and mortality in intracerebral haemorrhage after OAC »
Table of Contents: EAN 2019
Featured articles
Letter from the Editor
Alzheimer’s Disease and other Dementias
A necessary shift of focus to the earlier stages of Alzheimer’s
Antipsychotics increase mortality regardless of comorbidity
Epilepsy
Neuroinflammatory pathways as biomarkers and treatment targets
Long-term effect of recurrent febrile seizures
Migraine
The role of neurogenic inflammation in migraine
Multiple Sclerosis
Treating MS from disease onset
Randomised and observational studies comparing treatments
Autologous haematopoietic stem cell transplantation
Neuromuscular Disorders
Parkinson's Disease and other Movement Disorders
Inflammation may change the course of Parkinson’s disease
Opicapone: follow-up on the BIPARK I and II trials
Epigallocatechin gallate does not modify MSA progression
Stroke
Thrombo-inflammation during ischaemia/reperfusion
Related Articles
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com